[Analysis of clinical features of 6 patients with infantile type glycogen storage disease type II]

Juan Ding1, Yu Huang, Haipo Yang

  • 1Department of Pediatrics, Peking University First Hospital, Beijing 100034, China.

Insights

Glycogen storage disease type II (GSD II) in infants presents with muscle weakness and heart issues. Early consideration of GSD II is crucial for infants with both muscular and cardiac symptoms.

Area of Science:

  • Pediatric Genetics
  • Metabolic Disorders
  • Cardiology

Background:

  • Glycogen storage disease type II (GSD II), also known as Pompe disease, is a rare inherited metabolic disorder.
  • Infantile-onset GSD II is characterized by progressive muscle weakness and cardiorespiratory failure.
  • Accurate and timely diagnosis is critical for managing GSD II and improving patient outcomes.

Purpose of the Study:

  • To summarize the clinical features and diagnostic findings of Chinese infantile patients diagnosed with GSD II.
  • To identify key clinical indicators and diagnostic markers for infantile GSD II in the Chinese population.

Main Methods:

  • Retrospective review of clinical data from six Chinese infants diagnosed with GSD II between January 2012 and June 2014.
  • Analysis included clinical manifestations, blood biochemistry, cardiac imaging (echocardiogram, electrocardiogram), and genetic analysis of the acid alpha-glucosidase (GAA) gene.
  • Measurement of GAA enzyme activity in whole blood and GAA gene mutation analysis via PCR and direct sequencing.

Main Results:

  • All six patients exhibited generalized muscle weakness, hypotonia, and developmental delays; cardiac involvement, including left ventricular hypertrophy and cardiomegaly, was present in all.
  • Elevated creatine kinase (CK) levels and significantly reduced GAA enzyme activity were observed in all patients.
  • Genetic analysis identified eight pathogenic mutations in the GAA gene, with classic infantile cases showing a poor prognosis and early mortality.

Conclusions:

  • Infantile GSD II presents with consistent motor and cardiac manifestations, supported by biochemical, imaging, and enzymatic findings.
  • The study highlights the importance of considering GSD II in infants presenting with combined muscular disease and cardiac involvement.
  • Prompt diagnostic evaluation, including enzyme assays and genetic testing, is essential for early detection and management of infantile GSD II.
Abstract

Related Concept Videos

Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.8K
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
1.0K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K
Toxidromes: Clinical Features01:30

Toxidromes: Clinical Features

Toxidromes are specific patterns of symptoms resulting from toxic substance exposure. They help in the identification and treatment of poisoning. The symptoms of each toxidrome group indicate poisoning by a certain class of chemicals or drugs.1. Sympathomimetic: Stimulates the sympathetic nervous system. Symptoms include agitation, increased heart rate (HR), blood pressure (BP), respiratory rate (RR), temperature, and pupil size. Drugs like cocaine and amphetamines, along with tremors and...
128
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
1.1K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
2.2K